Rocket Pharmaceuticals Inc. (RCKT)
US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial
Rocket Pharmaceuticals said on Wednesday that the U.S. Food and Drug Administration has lifted the clinical hold on its gene therapy mid-stage trial.
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.
RCKT Stock Tanks on Patient Death in Danon Disease Study
Rocket Pharmaceuticals plunges after a patient death in its Danon disease study, prompting a voluntary dosing pause. The FDA puts a clinical hold on the study.
Rocket Pharmaceuticals shares plunge after FDA halts key gene therapy trial following patient death
Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) sank nearly 60% on Tuesday morning after the company disclosed that the US Food and Drug Administration had placed a clinical hold on its pivotal Phase II trial for Danon disease, a rare genetic heart disorder, following the death of a patient in the study. The patient experienced a serious adverse event (SAE) of capillary leak syndrome and subsequently died due to an acute systemic infection, according to reports.
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.
Rocket Pharma Out Of Orbit, But Ready For Relaunch
Rocket Pharmaceuticals' gene therapies offer long-term effects for cardiovascular and hematology diseases, addressing severe unmet needs like Danon Disease, which currently requires heart transplants. The near-term outlook driven by clinical milestones for RP-A601, RP-A501, and potential Kresladi approval, with the current share price at $5 offering significant value. Rocket has $372M in cash, funding operations through 1H 2026, but will likely need financing post-positive data readout or Kresladi approval for commercialization.
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.
Rocket Pharma Is A Buy At These Prices With Promising Data
Rocket Pharmaceuticals, Inc.'s RP-L201 for LAD-I faces FDA rejection but shows promising data; potential approval could unlock a $350M market. RP-L102 for Fanconi Anemia and RP-A501 for Danon Disease show strong clinical data, indicating significant market potential. Financially, Rocket Pharma has a limited cash runway of 2–4 quarters, dependent on FDA approvals and successful public offerings.
Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'
Shares of Rocket Pharmaceuticals (RCKT) jumped 5.5% intraday Wednesday as Jefferies initiated coverage of the biotech company with a "buy" rating on optimism about the experimental drugs in its pipeline. Jefferies also set a price target of $29, more than double its current value.
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst
On Monday, Rocket Pharmaceuticals, Inc. RCKT presented long-term safety and efficacy results from the Phase 1 study of RP-A501 in male patients with Danon disease.
